IS1947B - Setin bensýlamínópíperidín efnasambönd og lyfjablöndur þeirra - Google Patents

Setin bensýlamínópíperidín efnasambönd og lyfjablöndur þeirra

Info

Publication number
IS1947B
IS1947B IS4644A IS4644A IS1947B IS 1947 B IS1947 B IS 1947B IS 4644 A IS4644 A IS 4644A IS 4644 A IS4644 A IS 4644A IS 1947 B IS1947 B IS 1947B
Authority
IS
Iceland
Prior art keywords
pharmaceutical compositions
substituted
compounds
substituted benzylaminopiperidine
benzylaminopiperidine compounds
Prior art date
Application number
IS4644A
Other languages
English (en)
Other versions
IS4644A (is
Inventor
Satake Kunio
Shishido Yuji
Wakabayashi Hiroaki
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of IS4644A publication Critical patent/IS4644A/is
Publication of IS1947B publication Critical patent/IS1947B/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS4644A 1995-08-24 1997-12-30 Setin bensýlamínópíperidín efnasambönd og lyfjablöndur þeirra IS1947B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB9500683 1995-08-24
PCT/IB1996/000572 WO1997008144A1 (en) 1995-08-24 1996-06-10 Substituted benzylaminopiperidine compounds

Publications (2)

Publication Number Publication Date
IS4644A IS4644A (is) 1997-12-30
IS1947B true IS1947B (is) 2004-10-13

Family

ID=11004362

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4644A IS1947B (is) 1995-08-24 1997-12-30 Setin bensýlamínópíperidín efnasambönd og lyfjablöndur þeirra

Country Status (42)

Country Link
US (1) US6506775B1 (is)
EP (2) EP1114817B1 (is)
JP (1) JP3084069B2 (is)
KR (1) KR100288673B1 (is)
CN (1) CN1153764C (is)
AP (1) AP643A (is)
AR (1) AR006305A1 (is)
AT (2) ATE208377T1 (is)
AU (1) AU702698B2 (is)
BG (1) BG64126B1 (is)
BR (1) BR9609989A (is)
CA (1) CA2227814C (is)
CO (1) CO4480738A1 (is)
CZ (1) CZ297543B6 (is)
DE (2) DE69631390T2 (is)
DK (2) DK0861235T3 (is)
DZ (1) DZ2086A1 (is)
ES (2) ES2211684T3 (is)
HK (1) HK1014935A1 (is)
HR (1) HRP960386B1 (is)
HU (1) HU225480B1 (is)
IL (1) IL119078A (is)
IS (1) IS1947B (is)
MA (1) MA23961A1 (is)
MX (1) MX9801467A (is)
MY (1) MY114800A (is)
NO (1) NO310720B1 (is)
NZ (1) NZ308207A (is)
OA (1) OA10666A (is)
PE (2) PE20010700A1 (is)
PL (1) PL186773B1 (is)
PT (2) PT861235E (is)
RO (1) RO119299B1 (is)
RU (1) RU2152930C2 (is)
SI (2) SI1114817T1 (is)
SK (1) SK282925B6 (is)
TN (1) TNSN96107A1 (is)
TR (1) TR199800300T1 (is)
TW (1) TW340842B (is)
UA (1) UA48981C2 (is)
WO (1) WO1997008144A1 (is)
YU (1) YU49122B (is)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9706196A (es) * 1996-08-14 1998-02-28 Pfizer Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p.
TW426667B (en) * 1997-11-19 2001-03-21 Pfizer Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists
US6777428B1 (en) 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
GEP20043224B (en) * 1999-05-06 2004-04-26 Pfizer Prod Inc Substituted Benzolactam Compounds
RS49964B (sr) 1999-05-17 2008-09-29 Pfizer Products Inc., Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli
CA2374643C (en) * 1999-05-21 2006-02-14 Pfizer Products Inc. 1-trifluoromethyl-4-hydroxy-7-piperidinylaminomethylchroman derivatives as substance p antagonists
CA2324116A1 (en) * 1999-10-25 2001-04-25 Susan Beth Sobolov-Jaynes Nk-1 receptor antagonists and eletriptan for the treatment of migraine
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (en) * 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
US6911544B2 (en) 2002-10-23 2005-06-28 Pfizer Inc. Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine
US7608629B2 (en) 2003-04-18 2009-10-27 Eli Lilly And Company (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-HT1F agonists
WO2005113503A2 (en) * 2004-05-21 2005-12-01 Pfizer Products Inc. Metabolites of (+)-(2s, 3s)-3-(2-methoxy-5-trifluoromethoxybenzylamino)-2-phenyl-piperidine
JP5007226B2 (ja) 2004-07-15 2012-08-22 エーエムアール テクノロジー インコーポレイテッド アリールおよびヘテロアリール置換テトラヒドロイソキノリンならびにノルエピネフリン、ドーパミン、およびセロトニンの再取り込みを遮断するためのその利用方法
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
KR101589551B1 (ko) 2005-07-15 2016-02-02 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
CA2624030A1 (en) 2005-09-29 2007-04-12 Tianying Jian Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2946778A1 (en) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2109608B1 (en) 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
EP3103791B1 (en) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2009111354A2 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
EP2264029A4 (en) 2008-03-31 2011-08-24 Kowa Co 1,3-dihydroisobenzofuran DERIVATIVE
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
CN102458123A (zh) 2009-05-12 2012-05-16 阿尔巴尼分子研究公司 芳基、杂芳基和杂环取代的四氢异喹啉及其用途
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー (S)−7−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロイソキノリンの結晶形態およびその使用
KR101830447B1 (ko) 2009-05-12 2018-02-20 알바니 몰레큘라 리써치, 인크. 7-([1,2,4]트리아졸로[1,5-α]피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도
CN104945382B (zh) 2009-10-14 2020-02-07 默沙东公司 提高p53活性的取代的哌啶和其用途
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
JP6043285B2 (ja) 2010-08-02 2016-12-14 サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. 低分子干渉核酸(siNA)を用いたカテニン(カドヘリン結合型タンパク質)β1(CTNNB1)遺伝子発現のRNA干渉媒介性阻害
CN108676800B (zh) 2010-08-17 2022-11-11 瑟纳治疗公司 使用短干扰核酸(siNA)的乙型肝炎病毒(HBV)基因表达的RNA干扰介导的抑制
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
CN103732592A (zh) 2011-04-21 2014-04-16 默沙东公司 胰岛素样生长因子-1受体抑制剂
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3358013B1 (en) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
CN105050598B (zh) 2012-09-28 2018-04-27 默沙东公司 作为erk抑制剂的新型化合物
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
CA2892361A1 (en) 2012-11-28 2014-06-05 Merck Sharp & Dohme Corp. Use of a wee1 inhibitor for treating a cancer characterized by low pkmyt1 expression levels
AU2013361694B2 (en) 2012-12-20 2017-10-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
EP3525785A4 (en) 2016-10-12 2020-03-25 Merck Sharp & Dohme Corp. KDM5 INHIBITORS
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US5364943A (en) * 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
CA2106200C (en) * 1991-03-26 1996-11-19 Terry J. Rosen Stereoselective preparation of substituted piperidines
ATE142199T1 (de) * 1991-06-20 1996-09-15 Pfizer Fluoralkoxybenzylaminoderivate stickstoffhaltiger heterocyclen
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0653208A3 (en) * 1993-11-17 1995-10-11 Pfizer Substance P antagonists for the treatment or prevention of sunburn.
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
DE69623580T2 (de) * 1995-12-21 2003-01-09 Pfizer Inc., New York 3-((5-Substituierte Benzyl)Amino)-2-Phenylpiperidine als Substance-P-Antagonisten
US5990125A (en) 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer

Also Published As

Publication number Publication date
UA48981C2 (uk) 2002-09-16
CA2227814C (en) 2002-12-31
KR19990044077A (ko) 1999-06-25
YU49122B (sh) 2004-03-12
AU702698B2 (en) 1999-03-04
PT1114817E (pt) 2004-05-31
SI1114817T1 (en) 2004-06-30
SK20798A3 (en) 1999-03-12
HUP9901159A3 (en) 2000-05-29
DK1114817T3 (da) 2004-04-26
CN1193961A (zh) 1998-09-23
AP643A (en) 1998-04-24
BG102288A (en) 1998-09-30
RU2152930C2 (ru) 2000-07-20
NO980751L (no) 1998-02-23
JP3084069B2 (ja) 2000-09-04
BG64126B1 (bg) 2004-01-30
TW340842B (en) 1998-09-21
ES2163017T3 (es) 2002-01-16
HUP9901159A2 (hu) 1999-07-28
AU5776996A (en) 1997-03-19
AP9600850A0 (en) 1996-10-31
NO310720B1 (no) 2001-08-20
MX9801467A (es) 1998-05-31
PE20010700A1 (es) 2001-07-09
SI0861235T1 (en) 2002-04-30
CO4480738A1 (es) 1997-07-09
NO980751D0 (no) 1998-02-23
DE69616817T2 (de) 2002-04-04
JPH10510554A (ja) 1998-10-13
CN1153764C (zh) 2004-06-16
DE69631390D1 (de) 2004-02-26
HU225480B1 (en) 2006-12-28
OA10666A (en) 2002-11-25
CA2227814A1 (en) 1997-03-06
YU47896A (sh) 1998-12-23
IS4644A (is) 1997-12-30
TR199800300T1 (xx) 1998-06-22
PL186773B1 (pl) 2004-02-27
DE69616817D1 (de) 2001-12-13
CZ52198A3 (cs) 1999-01-13
MA23961A1 (fr) 1997-04-01
ES2211684T3 (es) 2004-07-16
WO1997008144A1 (en) 1997-03-06
CZ297543B6 (cs) 2007-02-07
HK1014935A1 (en) 1999-10-08
SK282925B6 (sk) 2003-01-09
EP1114817A1 (en) 2001-07-11
EP0861235A1 (en) 1998-09-02
DK0861235T3 (da) 2001-12-27
BR9609989A (pt) 1999-07-06
TNSN96107A1 (fr) 2005-03-15
PL325332A1 (en) 1998-07-20
KR100288673B1 (ko) 2001-05-02
PE1398A1 (es) 1998-02-27
HRP960386B1 (en) 2002-04-30
MY114800A (en) 2003-01-31
IL119078A (en) 2003-11-23
ATE208377T1 (de) 2001-11-15
US6506775B1 (en) 2003-01-14
NZ308207A (en) 1998-07-28
IL119078A0 (en) 1996-11-14
PT861235E (pt) 2002-03-28
EP1114817B1 (en) 2004-01-21
HRP960386A2 (en) 1998-04-30
ATE258166T1 (de) 2004-02-15
AR006305A1 (es) 1999-08-25
DE69631390T2 (de) 2004-11-25
RO119299B1 (ro) 2004-07-30
EP0861235B1 (en) 2001-11-07
DZ2086A1 (fr) 2002-07-22

Similar Documents

Publication Publication Date Title
IS1947B (is) Setin bensýlamínópíperidín efnasambönd og lyfjablöndur þeirra
IS4706A (is) Lyfjasamsetningar
CY2005007I1 (el) Φαρμακευτικες συνθεσεις που περιεχουν δαριφενακινη
NO20004345L (no) Farmasøytisk sammensetning
DK0747050T3 (da) Farmaceutiske sammensætninger indeholdende irbesartan
FI955144A (fi) Päällystetyt farmaseuttiset koostumukset
NO955034D0 (no) Nye substituerte 1H-imidazoler og farmasöytiske preparater inneholdende disse
DE69618587D1 (de) Chinazoline und pharmazeutische zusammensetzungen
FI944832A (fi) Farmaseuttinen koostumus
BR9610396A (pt) Formulação farmacêutica
PT703954E (pt) Composicoes de derivados de polifenois e sua preparacao
ITMI932540A0 (it) Composizione farmaceutica
DE69614407D1 (de) Pharmazeutische zusammensetzungen
LV11727A (lv) Farmaceitiska kompozicija
FI973229A (fi) Uusi farmaseuttinen koostumus
FI973280A (fi) Farmaseuttinen koostumus
ITMI942166A0 (it) Composizioni farmaceutiche miorilassanti
NO975365L (no) Benzopyraner og farmasöytiske sammensetninger inneholdende dem
NO973401D0 (no) Kortikosteroidinneholdende sammensetninger og fremstilling derav
NO308004B1 (no) Nye aminofenylfosfonsyreforbindelser og farmasøytiske sammensetninger inneholdende dem
LV10579A (lv) Farmaceitiska kompozicija
BR9606066A (pt) Composto e formulação farmacêutica
BR9605777A (pt) Composição farmacêutica
FI962738A0 (fi) Farmaseuttiset koostumukset
BR9605131A (pt) Composição farmacêutica